Nebula Genomics’ Goal Is To Make The Value of Genome Sequencing a Reality

This month’s “Company Spotlight” provides a closer look at Nebula Genomics, a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community.

Kamal Obbad, CEO and cofounder of Nebula Genomics discussed Nebula Genomics’ marketplace, the need their platform is addressing, and where the future of genomics data sharing and access will lead to.

Nebula Genomics is using blockchain to ensure that consumers maintain control of their data and are compensated for its use, so that the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The eight-person company is headquartered in San Francisco, CA, and was founded in 2017 by Harvard Genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Nebula Genomics has recently secured $4.3M in funding from leading venture capital firms including Khosla Ventures, Mayfield and Arch Ventures. The funds will support the company’s mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data. Nebula has also forged a partnership with Veritas Genetics, the leading whole genome sequencing and interpretation company, that will connect the Nebula marketplace to Veritas’ Arvados open-source software platform.

The following summarizes questions and answers from my dialogue with Kamal Obbad.

EB: Tell us more about Nebula Genomics – What scientific and business needs are you trying to address and what products/services do you offer? Blockchain is a critical component of Nebula Genomics – can you explain exactly how you apply this technology to your services?

Kamal Obbad: One of the main issues researchers and the pharma industry are facing today is access to large scale genomics data. The data as it exists today is very fragmented. It is generated in many different labs, by both nonprofit and for-profit Continue reading